Company Overview
Exact Sciences Corporation operates within the healthcare sector, specifically focusing on the diagnostics and research industry, where it provides cancer screening and diagnostic test products to markets both in the United States and internationally. The company's primary offering includes Cologuard, a non-invasive stool-based DNA screening test designed to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer, alongside the Cologuard Plus Test. As of the latest available data, the company holds a market capitalization of $19.84B and generates annual revenue of $3.25B, supported by a workforce of 7,100 employees. These valuation and revenue figures indicate that Exact Sciences commands a substantial position in the colorectal cancer screening landscape, reflecting significant market confidence despite the company's current lack of profitability.
Financial Health
The company reported revenue of $3.25B over the trailing twelve months, yet it posted a net income of -$207,948,992, while EBITDA stood at $71.46M. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses and other costs significantly outweigh the earnings before interest and taxes, resulting in a net loss. Despite the net loss, the company maintains a free cash flow of $281.87M, which provides a degree of financial flexibility to fund operations, research, and development without relying heavily on external financing. This positive cash flow is notable given the negative net income, suggesting that non-cash charges or timing differences in accruals are impacting the bottom line more than actual cash outflows. The gross margin is 69.7%, indicating a high ability to convert revenue into gross profit relative to the cost of goods sold, yet the operating margin sits at -9.3% and the profit margin at -6.4%, highlighting the pressure from selling, general, and administrative expenses. On the balance sheet, the company holds $964.71M in cash against $2.53B in debt, resulting in a debt-to-equity ratio of 105.57, which characterizes a highly leveraged financial position. The current ratio of 2.43 suggests that the company possesses strong short-term liquidity, as its current assets are more than twice its current liabilities. Furthermore, the return on equity is -8.7% and the return on assets is -1.6%, metrics that reveal management has not yet generated returns on the capital invested in the business, a common characteristic in growth-stage biotech firms.
Valuation Assessment
Exact Sciences Corporation trades with a P/E ratio (TTM) of N/A and a forward P/E of 55.28, a disparity that implies the market expects future earnings to turn positive and grow significantly to justify the current price. The price-to-book ratio is 8.26, indicating that the market values the company at more than eight times its net asset value, reflecting a high premium assigned to its intangible assets and future growth potential. Alternative valuation metrics such as the price-to-sales ratio of 6.11 and an EV/EBITDA of 299.59 suggest that the stock is priced aggressively relative to its sales and earnings generation, typical for companies with high growth expectations but current losses. The 52-week high is $104.00 and the 52-week low is $38.81, providing a range within which the stock has traded over the last year. Without the current share price explicitly listed in the available facts, the exact percentage deviation from the high or low cannot be calculated, but the wide range underscores the stock's sensitivity to market sentiment regarding the company's path to profitability. The beta of 1.44 indicates that the stock is more volatile than the broader market, moving with greater intensity to market swings, which aligns with the high forward P/E and the speculative nature of a loss-making healthcare company.
Growth & Income
Revenue growth (YoY) stands at 23.1%, while earnings growth (YoY) is N/A due to the company's current net loss status. Since earnings growth is not applicable, revenue growth is the primary driver of expansion, implying that the company is prioritizing top-line expansion and market share acquisition over immediate profitability. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available earnings and cash flows back into the business to fuel growth initiatives rather than returning capital to shareholders. This reinvestment strategy is consistent with the company's stage of development, where capital is directed toward expanding the reach of Cologuard and Cologuard Plus Test. Overall, the growth and income profile is defined by strong revenue expansion and a complete absence of dividend income, positioning the stock as a pure growth play dependent on the eventual transition to profitability.